Teva Pharma Industries Ltd ADR (TEVA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $51.92B
Last updated: Nov 17, 2026 at 11:06 AM ET
Teva Pharma Industries Ltd ADR (TEVA) Financials: Revenue, Profit and Cash Flow
Teva Pharma Industries Ltd ADR reported revenue of $17.26B for the fiscal year ended Dec 31, 2025, up 4.3% from the year before. That year, net income was $1.41B with a net margin of 8.2%, operating cash flow was $1.65B and free cash flow was $1.15B. The quarter ended Sep 30, 2026 had revenue of $4.39B and net income of $233.00M.
Revenue and Margins
The operating margin was 12.5% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue fell from $21.90B, a compound annual decline of 2.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $17.26B | +4.3% | 51.8% | 12.5% | 8.2% |
| Dec 2024 | $16.54B | +4.4% | 48.7% | -1.8% | -9.9% |
| Dec 2023 | $15.85B | +6.2% | 48.2% | 2.7% | -3.5% |
| Dec 2022 | $14.93B | -6.0% | 46.7% | -14.7% | -16.4% |
| Dec 2021 | $15.88B | -4.7% | 47.8% | 10.8% | 2.6% |
| Dec 2020 | $16.66B | -1.4% | 46.4% | -21.4% | -24.0% |
| Dec 2019 | $16.89B | -10.4% | 44.6% | -2.6% | -5.9% |
| Dec 2018 | $18.85B | -15.8% | 44.0% | -8.7% | -11.4% |
| Dec 2017 | $22.39B | +2.2% | 48.4% | -78.1% | -72.7% |
| Dec 2016 | $21.90B | N/A | 54.1% | 9.8% | 1.5% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income fell 46.2% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.26B | $16.54B | $15.85B | $14.93B | $15.88B | $16.66B | $16.89B | $18.85B | $22.39B | $21.90B |
| Cost of revenue | $8.32B | $8.48B | $8.20B | $7.95B | $8.28B | $8.93B | $9.35B | $10.56B | $11.56B | $10.04B |
| Gross profit | $8.94B | $8.06B | $7.64B | $6.97B | $7.59B | $7.73B | $7.54B | $8.30B | $10.82B | $11.86B |
| Research and development | $1.01B | $1.05B | $953.00M | $838.00M | $1.09B | $1.79B | $1.01B | $1.21B | $1.85B | $2.11B |
| Operating income | $2.16B | -$303.00M | $433.00M | -$2.20B | $1.72B | -$3.57B | -$443.00M | -$1.64B | -$17.48B | $2.15B |
| Net income | $1.41B | -$1.64B | -$559.00M | -$2.45B | $417.00M | -$3.99B | -$999.00M | -$2.15B | -$16.27B | $329.00M |
| EBITDA | $3.14B | $4.43B | $433.00M | -$925.00M | $4.41B | $4.61B | $4.44B | $186.00M | -$15.48B | $2.90B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.39B | $4.14B | $3.98B | $4.71B | $4.48B | $4.18B | $3.89B | $4.23B | $4.33B | $4.16B | $3.82B | $4.46B |
| Gross profit | $2.44B | $2.15B | $1.97B | $2.66B | $2.30B | $2.10B | $1.88B | $2.12B | $2.15B | $2.02B | $1.77B | $2.42B |
| Operating income | $714.00M | $149.00M | $652.00M | $300.00M | $882.00M | $455.00M | $519.00M | -$29.00M | -$51.00M | -$5.00M | -$218.00M | $756.00M |
| Net income | $233.00M | -$576.00M | $369.00M | $480.00M | $433.00M | $282.00M | $214.00M | -$217.00M | -$437.00M | -$846.00M | -$139.00M | $463.00M |
Balance Sheet
As of Dec 2025, total debt of $16.81B exceeded cash and equivalents by $13.25B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $40.75B | $39.33B | $43.48B | $44.01B | $47.67B | $50.64B | $57.47B | $60.68B | $70.61B | $92.89B |
| Current assets | $13.95B | $12.55B | $12.48B | $12.05B | $12.57B | $13.01B | $13.46B | $13.79B | $15.38B | $16.96B |
| Cash and equivalents | $3.56B | $3.30B | $3.23B | $2.80B | $2.17B | $2.18B | $1.98B | $1.78B | $963.00M | $988.00M |
| Total liabilities | $32.83B | $33.61B | $35.35B | $35.41B | $36.42B | $39.58B | $42.41B | $44.89B | $51.87B | $57.90B |
| Short-term debt | $1.82B | $1.78B | $1.67B | $2.11B | $1.43B | $3.19B | $2.35B | $2.22B | $3.65B | $3.28B |
| Long-term debt | $14.99B | $16.00B | $18.16B | $19.10B | $21.62B | $22.73B | $24.56B | $26.70B | $28.83B | $32.52B |
| Shareholder equity | $7.91B | $5.37B | $7.51B | $7.80B | $10.28B | $10.03B | $13.97B | $14.71B | $17.36B | $33.34B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $40.04B | $39.86B | $40.04B | $40.75B | $39.86B | $40.13B | $38.41B | $39.33B | $41.76B | $41.34B | $42.77B | $43.48B |
| Total liabilities | $32.06B | $32.10B | $31.81B | $32.84B | $32.60B | $33.30B | $32.15B | $33.61B | $35.37B | $34.77B | $35.23B | $35.35B |
| Cash and equivalents | $4.08B | $3.65B | $3.74B | $3.56B | $2.20B | $2.16B | $1.70B | $3.30B | $3.32B | $2.26B | $2.99B | $3.23B |
| Shareholder equity | $7.98B | $7.76B | $8.23B | $7.91B | $7.25B | $6.83B | $6.26B | $5.37B | $6.07B | $6.36B | $7.28B | $7.51B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 69.7% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.65B | $1.25B | $1.37B | $1.59B | $798.00M | $1.22B | $538.00M | $2.45B | $3.51B | $5.22B |
| Capital expenditures | $501.00M | $498.00M | $526.00M | $548.00M | $562.00M | $578.00M | $119.00M | $651.00M | $874.00M | $901.00M |
| Free cash flow | $1.15B | $749.00M | $842.00M | $1.04B | $236.00M | $638.00M | $419.00M | $1.79B | $2.63B | $4.32B |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | N/A | $52.00M | $22.00M | $1.16B | $1.56B |
| Investing cash flow | $737.00M | $792.00M | $968.00M | $656.00M | $1.52B | $863.00M | $1.35B | $1.87B | $2.16B | -$35.74B |
| Financing cash flow | -$2.15B | -$1.79B | -$1.91B | -$1.49B | -$2.17B | -$1.89B | -$241.00M | -$3.35B | -$5.75B | $25.22B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $241.00M | $411.00M | -$40.00M | $1.16B | $369.00M | $227.00M | -$105.00M | $575.00M | $693.00M | $103.00M | -$124.00M | $1.18B |
| Capital expenditures | $120.00M | $104.00M | $168.00M | $142.00M | $136.00M | $96.00M | $127.00M | $129.00M | $148.00M | $97.00M | $124.00M | $119.00M |
| Free cash flow | $121.00M | $307.00M | -$208.00M | $1.02B | $233.00M | $131.00M | -$232.00M | $446.00M | $545.00M | $6.00M | -$248.00M | $1.06B |
Frequently Asked Questions About TEVA
What is Teva Pharma Industries Ltd ADR's annual revenue?
Teva Pharma Industries Ltd ADR reported revenue of $17.26B for the fiscal year ended Dec 31, 2025.
How fast is Teva Pharma Industries Ltd ADR's revenue growing?
Revenue was up 4.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 5.0%.
Is Teva Pharma Industries Ltd ADR profitable?
Yes. Teva Pharma Industries Ltd ADR reported net income of $1.41B for the fiscal year ended Dec 31, 2025, with a net margin of 8.2%.
How much free cash flow does TEVA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $1.65B minus capital expenditures of $501.00M produced free cash flow of $1.15B.
How much debt does Teva Pharma Industries Ltd ADR have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $14.99B, short-term debt of $1.82B and cash and equivalents of $3.56B.
TEVA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors